---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-003"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ESK-001-003. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 39 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/esk-001-003"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-003

<a id="heading-3.1.7"></a>

## 3.1.7 ESK-001-003

<a id="heading-3.1.7.1"></a>

### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

#### Brief summary in the ClinicalTrials.gov record

> “Brief Summary Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.1-2"></a>

#### Pharmacokinetic and pharmacodynamic assessment for dose selection

> “Assessment of the PK/PD relationship on Day 14 (Figure 5) was performed to allow the selection of a suitable dose range for future clinical studies in patients with immune‐mediated diseases.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.2"></a>

### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

#### Study period and single site in Glendale, United States, in the published report

> “This was a phase I, single‐center, randomized, double‐blinded (with Sponsor unblinded), placebo‐controlled, parallel‐group, MD study of oral ESK‐001 immediate release tablet administration in healthy participants (NCT05431634), conducted from April 15, 2022 to September 20, 2022 at a facility in Glendale (US).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.2-2"></a>

#### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-05-12”
> “Primary Completion (Actual) 2022-12-01”
> “Study Completion (Actual) 2022-12-31”
> “First Submitted 2022-06-09”
> “First Posted 2022-06-24”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.2-3"></a>

#### Site in the ClinicalTrials.gov record

> “This study has 1 location”
> “Glendale, California, United States, 91206”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.2-4"></a>

#### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2023-05-09” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="heading-3.1.7.3"></a>

### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

#### Official title and design details in the ClinicalTrials.gov record

> “A Blinded, Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 Tablets Administered Over 14days to Healthy Participants”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-003” |
| Conditions | “Safety and Tolerability” |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “Double (ParticipantInvestigator)” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.3-2"></a>

#### Blinding, confinement, and 14-day dosing schedule

> “The Principal Investigator, clinical study personnel, and study participants were blinded to treatment with the Sponsor unblinded.”
> “Following the screening period from Day −29 to −2, participants were admitted to the facility from Day −1 to 16 for a 14‐day course of the study drug with first dose administration on Day 1, and returned 5–7 days after the last dose for final safety assessments.”
> “Randomization utilized a randomization code and restricted access area maintenance.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.3-3"></a>

#### Regulatory framework of the United States study

> “The study adhered to the 21 Code of Federal Regulation guideline, the principles of the Declaration of Helsinki, the ICH E6 (R2) Good Clinical Practice – Scientific Guideline, the requirements of national drug and data protection laws, in particular, the Health Insurance Portability and Accountability Act of 1996.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.4"></a>

### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

#### Inclusion and exclusion criteria in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Inclusion: age | “Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit” |
| Inclusion: health status | “Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters” |
| Inclusion: other | “Other inclusions as specified in the protocol” |
| Exclusion: prior exposure | “Participant has a prior exposure to ESK-001” |
| Exclusion: hypersensitivity | “Participant has a history of hypersensitivity to any of the ingredients of ESK-001” |
| Exclusion: other | “Other exclusions as specified in the protocol” |
| Ages eligible for study | “18 Years to 60 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="heading-3.1.7.5"></a>

### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

#### Tablet strengths and matching placebo

> “The study products included ESK‐001 30 mg tablet (Batch number: 25089), ESK‐001 10 mg tablet (Batch number: 25087), and matching placebos (30 mg tablet [Batch number: 25206], 10 mg tablet [Batch number: 25204]).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.5-2"></a>

#### Six dose regimens and the basis for dose and fasting conditions

> “Doses were 20 mg once daily (q.d.) fasted, 20 mg once every 12 h (Q12) fasted, 40 mg Q12 fasted, 10 mg q.d. fasted, 30 mg Q12 nonfasted, and 60 mg q.d. nonfasted.”
> “The dose levels were determined based on the SAD/MAD study results and relative bioavailability study data of the tablet vs. liquid formulation.”
> “The fasting requirement was adjusted for the last two cohorts, based on data from the FE cohort.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.5-3"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm description | Intervention |
| --- | --- | --- |
| “Placebo Comparator: Placebo” | “Placebo for ESK-001” | “Other: Placebo” |
| “Experimental: Experimental Drug ESK-001” | “Experimental Drug ESK-001” | “Multiple doses of ESK-001” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="heading-3.1.7.6"></a>

### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

#### 3.1.7.6.1 Rationale for Using Adverse Event Incidence as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

##### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Measure description | Time frame |
| --- | --- | --- | --- |
| Primary | “Incidence of Adverse Events (AEs)” | “Safety and tolerability” | “Up to 14 days” |
| Primary | “Incidence of Serious Adverse Events (SAEs)” | “Safety and tolerability” | “Up to 14 days” |
| Secondary | “The area under plasma concentration-time curve from time zero extrapolated to last measurable concentration (AUCt) for ESK001 on Day 1 and Day 14” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) for ESK001 on Day1 and Day 14” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The observed maximum plasma concentration (Cmax) for ESK001 on Day 1 and Day 14.” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The time to reach the observed maximum plasma concentration (tmax) for ESK001 on Day 1 and Day 14.” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “Apparent plasma elimination half-life (t½λz) for ESK001 on Day 1 and Day 14” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “Apparent clearance CL(Clearance)/F for ESK001 on Day 1” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) for ESK001 on Day 14” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The accumulation ratio for Cmax (RAC Cmax) for ESK001 on Day 14.” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “Cytokine induction of pSTAT expression and downstream cytokine production as a measure of tyk2 pathway inhibition by ESK001” | “Pharmacodynamics” | “14 days after first dose” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.6.1-2"></a>

##### Pharmacodynamic assessments: pSTAT1 flow cytometry and whole-blood RNA sequencing

> “The effect of ESK‐001 on exploratory PD and biomarker parameters was evaluated in the whole blood of healthy participants from the MD study.”
> “Flow cytometry analysis of pSTAT1 (phosphorylated signal transducer and activator of transcription 1) expression in T cells in IFNα‐stimulated whole blood and RNA sequencing of unstimulated whole blood was performed.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.6.1-3"></a>

##### Definitions of percentage pSTAT1 inhibition and the type I interferon and SIGLEC1 signatures

> “The percentage inhibition of pSTAT1 was calculated for each participant for each timepoint as the percentage change from baseline (Day 1 predose).”
> “RNA sequencing was performed to analyze type I IFN gene and SIGLEC1 signature, which were defined as the median transcript expression of the Dx Terity panel genes HERC5, RSAD2, IFI27, and IFIT1, and SIGLEC1, respectively.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.6.1-4"></a>

##### Urine collection and pharmacokinetic-pharmacodynamic sampling in the multiple-dose study

> “Urine was collected from all MD cohorts but only cohorts 20 mg q.d., 60 mg q.d., and 40 mg Q12 were analyzed.”
> “Parallel collection of PK samples alongside PD sampling enabled the determination of the ESK‐001 PK/PD relationship.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.7"></a>

### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

#### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

##### Planned cohort size and participants enrolled per cohort

> “Participants were randomized to six cohorts (planned cohort size: 8 participants) to receive ESK‐001 or placebo (3:1), with 49 participants (36 for ESK‐001 and 13 for placebo) enrolled per Sponsor's decision.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.7.1-2"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 49”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.7.1-3"></a>

##### Enrollment estimated at registration, June 2022, superseded in May 2023

> “Enrollment 48 [Estimated]”

Source: [ClinicalTrials.gov NCT05431634 version 1](https://clinicaltrials.gov/study/NCT05431634?tab=history&a=1)

<a id="heading-3.1.7.7.2"></a>

#### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

##### Steady-state assessment and software for pharmacokinetic and statistical analyses

> “Plasma ESK‐001 steady state was assessed by calculating the 90% confidence interval (CI) of the slope of the linear regression of loge (concentration at the end of a dose interval [C trough]) vs. time in the MD study.”
> “The PK analyses were conducted using Phoenix WinNonlin Version 8.3 or higher, and all statistical analyses were performed using SAS Version 9.4 (SAS Institute, Cary, North Carolina, USA).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.7.2-2"></a>

##### Data included in the pharmacokinetic-pharmacodynamic analysis

> “All available individual PD TYK2 inhibition data points (across all valid cohorts, doses, and timepoints) with matching PK measurements were included in the assessment.”
> “Individual PD results were plotted against their respective exposure (in μM) on a semi‐log scale graph and best‐fit curve (log inhibitor vs. response, four parameters) was generated in GraphPad Prism.”
> “Per protocol, PD samples were to be collected on Day 14, but for some participants, the PD samples were collected on Day 13.”
> “N = 6 participants, except for Cohort 30 mg Q12 Day 14 (N = 5).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.7.2-3"></a>

##### Exclusion of placebo participants with unexpected plasma concentrations

> “In the MD study, five participants receiving a placebo showed sparse unexpected ESK‐001 plasma concentrations but were excluded as per Sponsor's request.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.8"></a>

### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

#### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

##### Randomization and discontinuations in the multiple-dose study

> “In the MD study, 49 participants were randomized to study treatment (Figure 2).”
> “Five participants discontinued the study.”
> “Two participants discontinued the study drug and study due to TEAEs (see Safety and Tolerability results).”
> “One participant receiving ESK‐001 (Cohort 20 mg q.d. fasted) discontinued the study drug and study after the sixth dose due to psychotic behavior.”
> “Additionally, two participants receiving placebo discontinued the study drug and study due to withdrawal by participant (both for personal reasons, non‐safety‐related); one (Cohort 40 mg Q12 fasted) after the second dose on Day 10, and another (Cohort 30 mg Q12 nonfasted) after the first dose on Day 3.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.8.2"></a>

#### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

##### Race, ethnicity, sex, and body mass index in the multiple-dose study

> “Most participants were white and not Hispanic or Latin (Table S1).”
> “Overall, sex was balanced between cohorts receiving ESK‐001.”
> “The mean BMI ranged from 24.0 to 26.8 kg/m2.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.8.3"></a>

#### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

##### Absorption, half-life, dose proportionality, steady state, and accumulation with the tablet

> “ESK‐001 was rapidly absorbed into the systemic circulation with a median T max of 1.5–3.1 h on Day 1 following a single dose, and 1.1–2.2 h on Day 14 following multiple q.d. or Q12 doses (Figure 3b, Table 1).”
> “The mean t½ after the last dose on Day 14 ranged from 7.6 to 12.4 h across all q.d. or Q12 doses and no trend with dose or dose regimen was observed.”
> “Similarly, no trend with dose was observed for geometric mean apparent steady‐state volume of distribution (Vss/F) and mean apparent total plasma clearance (CL/F).”
> “After multiple q.d. doses and after the first dose administration of Q12 doses, AUC from time zero to time tau (AUC0–tau) appeared to increase in a dose‐proportional manner (slope estimates [95% CI] were 0.934 [0.62;1.25] and 0.992 [0.49, 1.49], respectively), although 95% CIs were wide.”
> “No definitive conclusion could be derived on dose proportionality for q.d. doses on Day 1 and for Q12 doses on Day 14.”
> “Steady state was achieved by Day 3 following q.d. and Q12 multiple doses.”
> “Following multiple q.d. doses, accumulation ratios (R ac) based on C max and AUC0–tau showed no to minimal accumulation of ESK‐001 (mean R ac C max ranged from 0.71 to 1.41 and mean R ac AUC from 0.80 to 1.39).”
> “Following multiple Q12 doses, there was an ~ 2‐fold accumulation of ESK‐001 (mean R ac C max ranged from 1.74 to 2.17 and mean R ac AUC from 1.74 to 2.42).”
> “The C trough levels at the highest ESK‐001 dose of 40 mg Q12 were maintained above the in vitro human whole blood (HWB) 90% pSTAT inhibitory concentration (IC90) threshold (Figure 3c).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-2"></a>

##### Plasma pharmacokinetic parameters by multiple-dose cohort on days 1 and 14

> “Summary of plasma PK parameters of ESK‐001 following administration of single and multiple doses.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

| Cohort and day (N = 6 per cohort) | Cmax, ng/mL | Ctrough, ng/mL | Tmax, h | AUC0–tau, h*ng/mL | t½, h | CL/F, L/h | Rac Cmax | Rac AUCtau |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 10 mg q.d. fasted, day 1 | “88.2 (42.7)” | “‐” | “2.02 (1.01–2.04)” | “630.8 (41.1)” | “‐” | “‐” | “‐” | “‐” |
| 10 mg q.d. fasted, day 14 | “99.5 (40.9)” | “11.8 (48.2)” | “1.60 (0.50–2.24)” | “795.8 (37.2)” | “9.22 (22.8)” | “12.6 (37.2)” | “1.13 (21.0)” | “1.26 (12.4)” |
| 20 mg q.d. fasted, day 1 | “171.4 (26.7)” | “‐” | “1.53 (0.51–2.07)” | “1338.0 (14.9)” | “‐” | “‐” | “‐” | “‐” |
| 20 mg q.d. fasted, day 14 | “132.0 (93.3)” | “15.1 (65.6)” | “2.10 (1.02–2.16)” | “1102.0 (71.4)” | “9.18 (36.7)” | “18.2 (71.4)” | “0.71 (80.2)” | “0.80 (79.9)” |
| 20 mg Q12 fasted, day 1 | “132.2 (20.9)” | “‐” | “2.01 (0.51–2.05)” | “793.1 (24.1)” | “‐” | “‐” | “‐” | “‐” |
| 20 mg Q12 fasted, day 14 | “287.1 (20.0)” | “108.7 (27.7)” | “2.06 (0.50–2.14)” | “1920.0 (17.3)” | “9.61 (7.6)” | “10.4 (17.3)” | “2.17 (32.7)” | “2.42 (25.6)” |
| 30 mg Q12 nonfasted, day 1 | “182.0 (46.6)” | “‐” | “2.09 (2.06–2.19)” | “1206.0 (38.7)” | “‐” | “‐” | “‐” | “‐” |
| 30 mg Q12 nonfasted, day 14 | “282.7 (24.0)” | “54.2 (306.4)” | “2.20 (2.12–4.19)” | “1878.0 (31.4)” | “7.60 (14.5)” | “16.0 (31.4)” | “1.74 (25.8)” | “1.74 (10.0)” |
| 60 mg q.d. nonfasted, day 1 | “356.7 (48.6)” | “‐” | “3.12 (1.13–4.07)” | “2934.0 (30.7)” | “‐” | “‐” | “‐” | “‐” |
| 60 mg q.d. nonfasted, day 14 | “503.8 (40.3)” | “45.5 (61.8)” | “2.09 (2.03–2.12)” | “4074.0 (33.7)” | “9.56 (20.2)” | “14.7 (33.7)” | “1.41 (34.4)” | “1.39 (30.5)” |
| 40 mg Q12 fasted, day 1 | “249.6 (25.9)” | “‐” | “2.06 (1.01–4.01)” | “1574.0 (25.4)” | “‐” | “‐” | “‐” | “‐” |
| 40 mg Q12 fasted, day 14 | “437.4 (49.0)” | “226.3 (31.3)” | “1.08 (1.04–2.13)” | “3246.0 (50.2)” | “12.41 (29.8)” | “12.3 (50.2)” | “1.75 (61.9)” | “2.06 (51.2)” |

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-3"></a>

##### Urinary excretion of unchanged drug in the multiple-dose study

> “Only a small amount of unchanged ESK‐001 was eliminated in urine.”
> “The mean %Fe (CV%) and CLr (CV%) were comparable for Cohort 60 mg q.d. (nonfasted) (0.43% [94.7%] and 63.8 mL/h [66.8%], respectively) and Cohort 40 mg Q12 (fasted) (0.37% [55.8%] and 46 mL/h [115.2%], respectively).”
> “Due to one outlier participant with very high %Fe (45.4%) and CLr (24.3 L/h) compared with the other participants in the same treatment group, the mean %Fe and CLr for the Cohort 20 mg q.d. (fasted) were higher (1.12% [935.9%] and 203.7 mL/h [4430.3%], respectively) than for the Cohorts 60 mg q.d. (nonfasted) and 40 mg Q12 (fasted).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-4"></a>

##### Elimination route in the congress poster's summary of the multiple-dose study

> “The primary elimination route was through liver metabolism, with <1% renal excretion.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="topic-3.1.7.8.3-5"></a>

##### Inhibition of IFNα-induced pSTAT1 in T cells by dose

> “In the MD study, IFNα‐induced pSTAT1 expression was analyzed in T cells from whole blood as a measure of TYK2 inhibition and confirmed robust pharmacologic activity of ESK‐001 with a clear dose‐dependent effect (Figure 4a).”
> “Maximal TYK2 pathway inhibition was achieved within 2–4 h for all doses >10 mg q.d., with dose‐dependent differences observable at later timepoints following the last dose.”
> “At the highest daily dose of 80 mg (administered as 40 mg Q12), maximal levels of TYK2 inhibition were achieved within 2–4 h and maintained throughout the Q12 dose interval.”
> “At the lowest total daily dose of 10 mg q.d., a partial TYK2 inhibition profile was achieved, with TYK2 inhibition peaking at <50% inhibition within 2–4 h and quickly returning to baseline TYK2 activity with minimal inhibition measured at 12 and 24 h.”
> “All dose levels returned toward normal TYK2 activity 24–48 h after the last dose on Day 14.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-6"></a>

##### Type I interferon gene signature and SIGLEC1 expression

> “The mRNA transcriptomics analysis showed clear dose‐dependent inhibition of type I IFN gene signature on Day 14 with full inhibition at higher doses, which was concordant with pSTAT1 functional assay results (4b).”
> “Similarly, clear dose‐dependent inhibition of expression of SIGLEC1 (sialic acid binding Ig like lectin 1), a novel TYK2‐responsive biomarker, was observed (Figure 4c).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-7"></a>

##### Downstream cytokine inhibition in the congress poster

> “Downstream pathway inhibition of IFNα induced CXCL10 and IL-12/IL-18 induced IFNγ production.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="topic-3.1.7.8.3-8"></a>

##### Pharmacokinetic-pharmacodynamic relationship at the highest and lowest doses

> “At the highest dose of 40 mg Q12, peak (2–4 h after the last dose) and trough (12 h after the last dose) samples showed maximal TYK2 inhibition, which aligned with PK exposures at or above the in vitro HWB pSTAT IC90 threshold and was maintained throughout the treatment period (Figure 5c).”
> “As expected at the lowest dose (10 mg q.d.), ESK‐001 demonstrated only a partial profile of TYK2 inhibition with limited TYK2 inhibition achieved at peak timepoints (2–4 h after the last dose), which was not maintained at trough timepoints (24 h after the last dose) (Figure 5b).”
> “ESK‐001 demonstrated a strong PK/PD relationship, with high predictability, low variability, and a clear sigmoidal exposure–response relationship with TYK2 inhibition.”
> “Higher levels of drug exposure above the IC90 guide point did not result in additional pharmacological effects.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-9"></a>

##### Dose range selected for the STRIDE phase 2 study

> “The PK/PD relationship was used to select the dose range of 10 mg q.d. to 40 mg Q12 for ESK‐001 treatment in phase II studies, including the STRIDE phase II study in plaque psoriasis (NCT05600036).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.8.4"></a>

#### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

#### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

##### Treatment-emergent adverse events by multiple-dose cohort

| Event | 10 mg q.d. fasted (N = 6) | 20 mg q.d. fasted (N = 6) | 20 mg Q12 fasted (N = 6) | 30 mg Q12 nonfasted (N = 6) | 60 mg q.d. nonfasted (N = 6) | 40 mg Q12 fasted (N = 6) | Total active (N = 36) | Pooled placebo (N = 13) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participant with at least 1 TEAE | “3 (50.0) [7]” | “5 (83.3) [11]” | “5 (83.3) [14]” | “5 (83.3) [10]” | “4 (66.7) [16]” | “5 (83.3) [14]” | “27 (75.0) [72]” | “11 (84.6) [19]” |
| Mild | “3 (50.0) [6]” | “5 (83.3) [10]” | “5 (83.3) [14]” | “5 (83.3) [9]” | “4 (66.7) [11]” | “5 (83.3) [14]” | “27 (75.0) [64]” | “11 (84.6) [18]” |
| Moderate | “1 (16.7) [1]” | “1 (16.7) [1]” | “0” | “1 (16.7) [1]” | “3 (50.0) [5]” | “0” | “6 (16.7) [8]” | “1 (7.7) [1]” |
| Severe | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| TEAEs considered related to the study drug | “1 (16.7) [2]” | “2 (33.3) [4]” | “1 (16.7) [1]” | “3 (50.0) [3]” | “4 (66.7) [11]” | “4 (66.7) [8]” | “15 (41.7) [29]” | “1 (7.7) [1]” |
| TEAEs leading to study drug discontinuation | “0” | “0” | “0” | “1 (16.7) [1]” | “0” | “0” | “1 (2.8) [1]” | “1 (7.7) [1]” |
| Any serious TEAE | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| Erythema | “2 (33.3) [2]” | “5 (83.3) [6]” | “5 (83.3) [5]” | “4 (66.7) [5]” | “2 (33.3) [2]” | “2 (33.3) [2]” | “20 (55.6) [22]” | “9 (69.2) [11]” |
| Headache | “0” | “3 (50.0) [5]” | “2 (33.3) [2]” | “1 (16.7) [1]” | “4 (66.7) [9]” | “4 (66.7) [8]” | “14 (38.9) [25]” | “1 (7.7) [1]” |
| Gastrointestinal disorders | “0” | “0” | “1 (16.7) [1]” | “1 (16.7) [1]” | “2 (33.3) [2]” | “1 (16.7) [1]” | “5 (13.9) [5]” | “1 (7.7) [1]” |
| Psychiatric disorders | “1 (16.7) [1]” | “0” | “0” | “0” | “0” | “1 (16.7) [1]” | “2 (5.6) [2]” | “1 (7.7) [1]” |
| Dysmenorrhoea | “0” | “0” | “1 (16.7) [1]” | “0” | “0” | “0” | “1 (2.8) [1]” | “2 (15.4) [2]” |

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “Events occurring in >1 participant per cohort or pooled placebo group by SOC and PT are reported.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.5-2"></a>

##### Incidence, severity, relatedness, discontinuations, and laboratory findings in the multiple-dose study

> “Thirty‐eight (77.6%) participants experienced 91 TEAEs; 27 (75.0%) participants receiving ESK‐001 experienced 72 TEAEs and 11 (84.6%) participants receiving placebo experienced 19 TEAEs.”
> “Most TEAEs (90.1%) were mild in severity; all other TEAEs were moderate in severity.”
> “There was no dose‐dependent increase in the number of TEAEs or meaningful change in the severity levels observed.”
> “The frequency of headaches appeared to increase with increasing dose of ESK‐001; however, most headaches (80.8%) were observed to be mild in severity across all dose levels and resolved without sequalae.”
> “Two participants discontinued the study drug and study due to TEAEs; one participant receiving ESK‐001 (Cohort 30 mg Q12 nonfasted) due to rash morbilliform (considered study drug‐related), and one receiving placebo (Cohort 60 mg q.d. nonfasted) due to COVID‐19 (considered not study drug‐related); both TEAEs were mild in severity.”
> “The most common TEAEs (reported in ≥30% of the participants in any group) by preferred term were erythema and headache.”
> “Events of erythema were secondary to skin taping for a sample collection procedure.”
> “Fifteen (41.7%) participants receiving ESK‐001 experienced 29 TEAEs considered related to the study drug and 1 (7.7%) participant receiving a placebo experienced a TEAE considered related to placebo.”
> “Minor fluctuations occurred in coagulation, clinical chemistry, and urinalysis parameters, but without treatment‐related trends.”
> “Two participants reported an abnormal clinically meaningful laboratory value; one for Strep A2 rapid screen on Day 8, and one for SARS‐CoV‐2 RNA on Day 9.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.5-3"></a>

##### Deaths, serious events, and adverse events of special interest in the congress poster's safety summary

> “ESK-001 was generally well tolerated across cohorts. No deaths or serious treatment-emergent adverse events (TEAEs) were observed.”
> “No major adverse cardiovascular events, malignancies, venous thromboembolism events or adverse trends in laboratory parameters occurred.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="heading-3.1.7.9"></a>

### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

#### Summary

- The authors advise caution in interpreting the dose proportionality analysis because of the small number of participants, the limited q.d. and Q12 dose range, and the wide 95% CIs; no definitive conclusion could be derived for q.d. doses on Day 1 and Q12 doses on Day 14.
- Participants were 49 healthy adults (36 envudeucitinib, 13 placebo) treated for 14 days at one site.
- The last two cohorts (30 mg Q12 and 60 mg q.d.) were dosed nonfasted, while the other cohorts were dosed fasted.
- The Sponsor was unblinded, and five placebo participants with unexpected ESK-001 plasma concentrations were excluded at the Sponsor's request.
- Some pharmacodynamic samples were collected on Day 13 instead of Day 14, and urine was analyzed for only 3 of the 6 cohorts, with one outlier participant raising the 20 mg q.d. means.
- Erythema, the most common TEAE with headache, was secondary to skin taping for a sample collection procedure.
- The article describes a parallel-group study conducted from April 15, 2022 to September 20, 2022; the ClinicalTrials.gov record lists sequential assignment, a start on 2022-05-12, and completion on 2022-12-31, and reads “No Results Posted”.

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/); [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.9-2"></a>

#### Small sample and limited dose range for the dose proportionality analysis

> “Furthermore, in the MD study, the results of statistical analysis of the dose proportionality should be cautiously interpreted in light of the small number of participants included in the analysis, the limited q.d. and Q12 dose range examined, and the wide 95% CI around the estimated slopes.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
